Results on the use of imatinib (Gleevec), a KI with high activity against KIT and PDGFR, have been disappointing with responses possibly correlated with either KIT mutation or high-level KIT protein expression (e.g. ≥75% of tumor cells) [52]. Here, KIT is linked to neoplasm.